AU2019328532A1 - Inhibition of RIP kinases for treating neurodegenerative disorders - Google Patents

Info

Publication number

AU2019328532A1

AU2019328532A1 AU2019328532A AU2019328532A AU2019328532A1 AU 2019328532 A1 AU2019328532 A1 AU 2019328532A1 AU 2019328532 A AU2019328532 A AU 2019328532A AU 2019328532 A AU2019328532 A AU 2019328532A AU 2019328532 A1 AU2019328532 A1 AU 2019328532A1

Authority

AU

Australia

Prior art keywords

ripk2

disease

inhibitor

microglia

nod2

Prior art date

2018-08-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 96
• 108091000080 Phosphotransferase Proteins 0.000 title claims description 66
• 102000020233 phosphotransferase Human genes 0.000 title claims description 64
• 230000005764 inhibitory process Effects 0.000 title description 21
• 108090000829 Ribosome Inactivating Proteins Proteins 0.000 title description 2
• 102100022419 RPA-interacting protein Human genes 0.000 title 1
• 239000003112 inhibitor Substances 0.000 claims abstract description 172
• 238000000034 method Methods 0.000 claims abstract description 143
• 230000004770 neurodegeneration Effects 0.000 claims abstract description 55
• 239000003814 drug Substances 0.000 claims abstract description 33
• 229940124597 therapeutic agent Drugs 0.000 claims abstract description 22
• 108090000623 proteins and genes Proteins 0.000 claims description 136
• 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 claims description 125
• 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 claims description 125
• 210000000274 microglia Anatomy 0.000 claims description 117
• 230000014509 gene expression Effects 0.000 claims description 113
• 102000004169 proteins and genes Human genes 0.000 claims description 89
• 230000000694 effects Effects 0.000 claims description 75
• 210000001130 astrocyte Anatomy 0.000 claims description 74
• 208000018737 Parkinson disease Diseases 0.000 claims description 70
• 230000004913 activation Effects 0.000 claims description 64
• 208000024827 Alzheimer disease Diseases 0.000 claims description 47
• 210000003169 central nervous system Anatomy 0.000 claims description 47
• 150000001875 compounds Chemical class 0.000 claims description 46
• 210000002865 immune cell Anatomy 0.000 claims description 36
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
• 230000002401 inhibitory effect Effects 0.000 claims description 25
• 108700012920 TNF Proteins 0.000 claims description 23
• 230000015572 biosynthetic process Effects 0.000 claims description 23
• 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 19
• 201000010099 disease Diseases 0.000 claims description 19
• 229960002584 gefitinib Drugs 0.000 claims description 19
• 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 17
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 17
• 230000006724 microglial activation Effects 0.000 claims description 17
• 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 16
• 108090001005 Interleukin-6 Proteins 0.000 claims description 16
• 231100000189 neurotoxic Toxicity 0.000 claims description 16
• 230000002887 neurotoxic effect Effects 0.000 claims description 16
• XLOGLWKOHPIJLV-UHFFFAOYSA-N 6-tert-butylsulfonyl-n-(5-fluoro-1h-indazol-3-yl)quinolin-4-amine Chemical compound C1=C(F)C=C2C(NC3=CC=NC4=CC=C(C=C43)S(=O)(=O)C(C)(C)C)=NNC2=C1 XLOGLWKOHPIJLV-UHFFFAOYSA-N 0.000 claims description 14
• 230000002757 inflammatory effect Effects 0.000 claims description 14
• 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 claims description 13
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 12
• 230000001419 dependent effect Effects 0.000 claims description 11
• 238000000338 in vitro Methods 0.000 claims description 11
• 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 claims description 10
• 108010040003 polyglutamine Proteins 0.000 claims description 10
• 150000003839 salts Chemical class 0.000 claims description 10
• 238000001727 in vivo Methods 0.000 claims description 9
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 8
• 208000035475 disorder Diseases 0.000 claims description 8
• 108010057466 NF-kappa B Proteins 0.000 claims description 7
• 102000003945 NF-kappa B Human genes 0.000 claims description 7
• 206010012289 Dementia Diseases 0.000 claims description 6
• 201000006474 Brain Ischemia Diseases 0.000 claims description 5
• 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
• 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 5
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 5
• 208000013171 Fahr disease Diseases 0.000 claims description 5
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 5
• 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 5
• 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims description 5
• 208000012583 Menkes disease Diseases 0.000 claims description 5
• 208000001089 Multiple system atrophy Diseases 0.000 claims description 5
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 5
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 5
• 102000029797 Prion Human genes 0.000 claims description 5
• 108091000054 Prion Proteins 0.000 claims description 5
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 5
• 208000006011 Stroke Diseases 0.000 claims description 5
• 208000018839 Wilson disease Diseases 0.000 claims description 5
• 201000002922 basal ganglia calcification Diseases 0.000 claims description 5
• 208000016791 bilateral striopallidodentate calcinosis Diseases 0.000 claims description 5
• 208000029028 brain injury Diseases 0.000 claims description 5
• 206010008118 cerebral infarction Diseases 0.000 claims description 5
• 208000008675 hereditary spastic paraplegia Diseases 0.000 claims description 5
• 201000010901 lateral sclerosis Diseases 0.000 claims description 5
• 208000005264 motor neuron disease Diseases 0.000 claims description 5
• 201000006417 multiple sclerosis Diseases 0.000 claims description 5
• 229920000155 polyglutamine Polymers 0.000 claims description 5
• 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 5
• 229960003787 sorafenib Drugs 0.000 claims description 5
• 208000020431 spinal cord injury Diseases 0.000 claims description 5
• KTSDBMVHAKWDRK-UHFFFAOYSA-N 4-chloro-7,10-dioxa-13,17,18,21-tetrazatetracyclo[12.5.2.12,6.017,20]docosa-1(20),2(22),3,5,14(21),15,18-heptaene Chemical compound Clc1cc2OCCOCCNc3ccn4ncc(-c(c1)c2)c4n3 KTSDBMVHAKWDRK-UHFFFAOYSA-N 0.000 claims description 4
• 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
• 102000003802 alpha-Synuclein Human genes 0.000 claims description 4
• 108090000185 alpha-Synuclein Proteins 0.000 claims description 4
• 230000003959 neuroinflammation Effects 0.000 claims description 4
• 230000003961 neuronal insult Effects 0.000 claims description 4
• 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 3
• 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 3
• CDMGBJANTYXAIV-UHFFFAOYSA-N SB 203580 Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 CDMGBJANTYXAIV-UHFFFAOYSA-N 0.000 claims description 3
• PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 3
• 229960001131 ponatinib Drugs 0.000 claims description 3
• FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 3
• 229960004836 regorafenib Drugs 0.000 claims description 3
• 230000035605 chemotaxis Effects 0.000 claims description 2
• LEBSTCDZKUSVOY-UHFFFAOYSA-N n-[2-[4-amino-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-2-methylpropyl]pyridine-4-carboxamide Chemical compound C1=CC(C)=CC=C1C1=NN(C(C)(C)CNC(=O)C=2C=CN=CC=2)C2=NC=NC(N)=C12 LEBSTCDZKUSVOY-UHFFFAOYSA-N 0.000 claims description 2
• 239000000203 mixture Substances 0.000 abstract description 44
• 108010079933 Receptor-Interacting Protein Serine-Threonine Kinase 2 Proteins 0.000 abstract description 5
• 238000012216 screening Methods 0.000 abstract description 5
• 102000013070 Receptor-Interacting Protein Serine-Threonine Kinase 2 Human genes 0.000 abstract description 4
• 210000004027 cell Anatomy 0.000 description 67
• 241000699670 Mus sp. Species 0.000 description 61
• 150000007523 nucleic acids Chemical group 0.000 description 59
• 230000009368 gene silencing by RNA Effects 0.000 description 56
• 108020004999 messenger RNA Proteins 0.000 description 56
• 102000039446 nucleic acids Human genes 0.000 description 53
• 108020004707 nucleic acids Proteins 0.000 description 53
• 108091030071 RNAI Proteins 0.000 description 51
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 47
• 239000002953 phosphate buffered saline Substances 0.000 description 47
• 238000002347 injection Methods 0.000 description 45
• 239000007924 injection Substances 0.000 description 45
• 241000699666 Mus <mouse, genus> Species 0.000 description 40
• 238000011282 treatment Methods 0.000 description 38
• 210000004556 brain Anatomy 0.000 description 33
• 238000012360 testing method Methods 0.000 description 33
• 230000000692 anti-sense effect Effects 0.000 description 32
• 210000001519 tissue Anatomy 0.000 description 32
• 239000000523 sample Substances 0.000 description 28
• 239000000047 product Substances 0.000 description 27
• 238000011529 RT qPCR Methods 0.000 description 25
• 239000003795 chemical substances by application Substances 0.000 description 25
• 241000282414 Homo sapiens Species 0.000 description 23
• 230000027455 binding Effects 0.000 description 22
• 230000000295 complement effect Effects 0.000 description 22
• 150000003384 small molecules Chemical class 0.000 description 22
• 108020004414 DNA Proteins 0.000 description 21
• 239000008194 pharmaceutical composition Substances 0.000 description 21
• 210000001642 activated microglia Anatomy 0.000 description 20
• 210000002569 neuron Anatomy 0.000 description 20
• 102000053602 DNA Human genes 0.000 description 19
• 108091027967 Small hairpin RNA Proteins 0.000 description 19
• 238000003364 immunohistochemistry Methods 0.000 description 19
• 238000003753 real-time PCR Methods 0.000 description 19
• 102000008682 Argonaute Proteins Human genes 0.000 description 18
• 108010088141 Argonaute Proteins Proteins 0.000 description 18
• 239000002773 nucleotide Substances 0.000 description 18
• 239000000243 solution Substances 0.000 description 18
• 230000000052 comparative effect Effects 0.000 description 17
• 239000002609 medium Substances 0.000 description 17
• 125000003729 nucleotide group Chemical group 0.000 description 17
• -1 DNAzymse Proteins 0.000 description 16
• 241001465754 Metazoa Species 0.000 description 16
• 108020004459 Small interfering RNA Proteins 0.000 description 16
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
• 239000012528 membrane Substances 0.000 description 15
• 210000001259 mesencephalon Anatomy 0.000 description 15
• 210000001577 neostriatum Anatomy 0.000 description 15
• 230000001225 therapeutic effect Effects 0.000 description 15
• 239000002299 complementary DNA Substances 0.000 description 14
• 230000002255 enzymatic effect Effects 0.000 description 14
• 108091034117 Oligonucleotide Proteins 0.000 description 13
• 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 13
• 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 13
• 238000005516 engineering process Methods 0.000 description 13
• 230000003834 intracellular effect Effects 0.000 description 13
• 108090000994 Catalytic RNA Proteins 0.000 description 12
• 102000053642 Catalytic RNA Human genes 0.000 description 12
• 102000019355 Synuclein Human genes 0.000 description 12
• 108050006783 Synuclein Proteins 0.000 description 12
• 230000007170 pathology Effects 0.000 description 12
• 238000002360 preparation method Methods 0.000 description 12
• 108091092562 ribozyme Proteins 0.000 description 12
• 210000003523 substantia nigra Anatomy 0.000 description 12
• 230000008685 targeting Effects 0.000 description 12
• 238000003556 assay Methods 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 108090000765 processed proteins & peptides Proteins 0.000 description 11
• 239000013598 vector Substances 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 10
• 238000011818 5xFAD mouse Methods 0.000 description 10
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
• 102100029424 Nucleotide-binding oligomerization domain-containing protein 1 Human genes 0.000 description 10
• 210000004558 lewy body Anatomy 0.000 description 10
• 230000001404 mediated effect Effects 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 102000005962 receptors Human genes 0.000 description 10
• 108020003175 receptors Proteins 0.000 description 10
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
• 238000001262 western blot Methods 0.000 description 10
• 238000010453 CRISPR/Cas method Methods 0.000 description 9
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 230000008236 biological pathway Effects 0.000 description 9
• 239000006285 cell suspension Substances 0.000 description 9
• 239000000411 inducer Substances 0.000 description 9
• 230000001939 inductive effect Effects 0.000 description 9
• 102000004196 processed proteins & peptides Human genes 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 239000011780 sodium chloride Substances 0.000 description 9
• 239000000758 substrate Substances 0.000 description 9
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
• 101001125032 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 1 Proteins 0.000 description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 description 8
• 102000001253 Protein Kinase Human genes 0.000 description 8
• 238000010521 absorption reaction Methods 0.000 description 8
• 210000005013 brain tissue Anatomy 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 210000003618 cortical neuron Anatomy 0.000 description 8
• 238000011534 incubation Methods 0.000 description 8
• 238000002843 lactate dehydrogenase assay Methods 0.000 description 8
• 108060006633 protein kinase Proteins 0.000 description 8
• 239000003981 vehicle Substances 0.000 description 8
• 108091033409 CRISPR Proteins 0.000 description 7
• 102000004127 Cytokines Human genes 0.000 description 7
• 108090000695 Cytokines Proteins 0.000 description 7
• 241000282412 Homo Species 0.000 description 7
• 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 7
• 102100040247 Tumor necrosis factor Human genes 0.000 description 7
• 230000002159 abnormal effect Effects 0.000 description 7
• 239000000074 antisense oligonucleotide Substances 0.000 description 7
• 238000012230 antisense oligonucleotides Methods 0.000 description 7
• QQFBQBDINHJDMN-UHFFFAOYSA-N ethyl 2-trimethylsilylacetate Chemical compound CCOC(=O)C[Si](C)(C)C QQFBQBDINHJDMN-UHFFFAOYSA-N 0.000 description 7
• 238000010362 genome editing Methods 0.000 description 7
• 210000001320 hippocampus Anatomy 0.000 description 7
• 238000001802 infusion Methods 0.000 description 7
• 108091070501 miRNA Proteins 0.000 description 7
• 238000010384 proximity ligation assay Methods 0.000 description 7
• 102000004533 Endonucleases Human genes 0.000 description 6
• 108010042407 Endonucleases Proteins 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 6
• 231100000416 LDH assay Toxicity 0.000 description 6
• 101710163270 Nuclease Proteins 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 6
• 238000010802 RNA extraction kit Methods 0.000 description 6
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
• 239000013543 active substance Substances 0.000 description 6
• 238000003349 alamar blue assay Methods 0.000 description 6
• 230000000903 blocking effect Effects 0.000 description 6
• 230000008499 blood brain barrier function Effects 0.000 description 6
• 210000001218 blood-brain barrier Anatomy 0.000 description 6
• 230000015556 catabolic process Effects 0.000 description 6
• 230000003833 cell viability Effects 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 239000003636 conditioned culture medium Substances 0.000 description 6
• 238000006731 degradation reaction Methods 0.000 description 6
• 230000009977 dual effect Effects 0.000 description 6
• 239000002158 endotoxin Substances 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 239000013604 expression vector Substances 0.000 description 6
• 238000012744 immunostaining Methods 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 230000002025 microglial effect Effects 0.000 description 6
• 238000010172 mouse model Methods 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 239000013610 patient sample Substances 0.000 description 6
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
• 230000026731 phosphorylation Effects 0.000 description 6
• 238000006366 phosphorylation reaction Methods 0.000 description 6
• 102000040430 polynucleotide Human genes 0.000 description 6
• 108091033319 polynucleotide Proteins 0.000 description 6
• 239000002157 polynucleotide Substances 0.000 description 6
• 238000012545 processing Methods 0.000 description 6
• 238000010839 reverse transcription Methods 0.000 description 6
• 230000011664 signaling Effects 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 102100021579 Enhancer of filamentation 1 Human genes 0.000 description 5
• 101000898310 Homo sapiens Enhancer of filamentation 1 Proteins 0.000 description 5
• 238000012347 Morris Water Maze Methods 0.000 description 5
• BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 5
• 241000283973 Oryctolagus cuniculus Species 0.000 description 5
• 229930040373 Paraformaldehyde Natural products 0.000 description 5
• 229930182555 Penicillin Natural products 0.000 description 5
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
• 238000010171 animal model Methods 0.000 description 5
• 238000004630 atomic force microscopy Methods 0.000 description 5
• 210000004748 cultured cell Anatomy 0.000 description 5
• 230000016396 cytokine production Effects 0.000 description 5
• 229950006137 dexfosfoserine Drugs 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 238000011013 endotoxin removal Methods 0.000 description 5
• 230000030279 gene silencing Effects 0.000 description 5
• 238000003119 immunoblot Methods 0.000 description 5
• 239000004615 ingredient Substances 0.000 description 5
• 229940043355 kinase inhibitor Drugs 0.000 description 5
• 238000011813 knockout mouse model Methods 0.000 description 5
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
• 230000005012 migration Effects 0.000 description 5
• 238000013508 migration Methods 0.000 description 5
• 230000007135 neurotoxicity Effects 0.000 description 5
• 229920002866 paraformaldehyde Polymers 0.000 description 5
• 229940049954 penicillin Drugs 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 5
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
• 230000004481 post-translational protein modification Effects 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 230000000770 proinflammatory effect Effects 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 238000003756 stirring Methods 0.000 description 5
• 229960005322 streptomycin Drugs 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 230000009182 swimming Effects 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• 231100000331 toxic Toxicity 0.000 description 5
• 230000002588 toxic effect Effects 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• 238000004627 transmission electron microscopy Methods 0.000 description 5
• ZKSOYIKYGANSGO-UHFFFAOYSA-N 2-fluoropropane-1,2-diol Chemical compound CC(O)(F)CO ZKSOYIKYGANSGO-UHFFFAOYSA-N 0.000 description 4
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 108091033380 Coding strand Proteins 0.000 description 4
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
• 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• 102100023387 Endoribonuclease Dicer Human genes 0.000 description 4
• 108700039887 Essential Genes Proteins 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 239000000020 Nitrocellulose Substances 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• 102000052376 Piwi domains Human genes 0.000 description 4
• 108700038049 Piwi domains Proteins 0.000 description 4
• 101150081826 RIPK2 gene Proteins 0.000 description 4
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
• PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
• 102000006382 Ribonucleases Human genes 0.000 description 4
• 108010083644 Ribonucleases Proteins 0.000 description 4
• 229940124639 Selective inhibitor Drugs 0.000 description 4
• 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 4
• 210000001056 activated astrocyte Anatomy 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 239000000427 antigen Substances 0.000 description 4
• 102000036639 antigens Human genes 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
• 239000013068 control sample Substances 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 239000000835 fiber Substances 0.000 description 4
• 239000012634 fragment Substances 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 238000012226 gene silencing method Methods 0.000 description 4
• 238000011065 in-situ storage Methods 0.000 description 4
• 229960003299 ketamine Drugs 0.000 description 4
• 238000000021 kinase assay Methods 0.000 description 4
• 102000006240 membrane receptors Human genes 0.000 description 4
• 238000010232 migration assay Methods 0.000 description 4
• 229920001220 nitrocellulos Polymers 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
• 239000010452 phosphate Substances 0.000 description 4
• 230000001323 posttranslational effect Effects 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 210000002243 primary neuron Anatomy 0.000 description 4
• 238000011084 recovery Methods 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 238000007423 screening assay Methods 0.000 description 4
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
• 239000011550 stock solution Substances 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 230000029663 wound healing Effects 0.000 description 4
• 108091023037 Aptamer Proteins 0.000 description 3
• 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 3
• 108091032955 Bacterial small RNA Proteins 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 108010017384 Blood Proteins Proteins 0.000 description 3
• 102000004506 Blood Proteins Human genes 0.000 description 3
• 102000011727 Caspases Human genes 0.000 description 3
• 108010076667 Caspases Proteins 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 108010053770 Deoxyribonucleases Proteins 0.000 description 3
• 102000016911 Deoxyribonucleases Human genes 0.000 description 3
• 102100029638 Dual serine/threonine and tyrosine protein kinase Human genes 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 3
• 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
• 206010018341 Gliosis Diseases 0.000 description 3
• 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 description 3
• 101000865739 Homo sapiens Dual serine/threonine and tyrosine protein kinase Proteins 0.000 description 3
• 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 description 3
• 101001109137 Homo sapiens Receptor-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 3
• 101001089248 Homo sapiens Receptor-interacting serine/threonine-protein kinase 4 Proteins 0.000 description 3
• 101000733257 Homo sapiens Rho guanine nucleotide exchange factor 28 Proteins 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 101710156256 Myosin phosphatase Rho-interacting protein Proteins 0.000 description 3
• 241000169176 Natronobacterium gregoryi Species 0.000 description 3
• 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
• 239000004677 Nylon Substances 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• 101710138590 Receptor-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 3
• 102100033734 Receptor-interacting serine/threonine-protein kinase 4 Human genes 0.000 description 3
• 108020004682 Single-Stranded DNA Proteins 0.000 description 3
• 230000001668 ameliorated effect Effects 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 230000000844 anti-bacterial effect Effects 0.000 description 3
• 108091007433 antigens Proteins 0.000 description 3
• 108010006523 asialoglycoprotein receptor Proteins 0.000 description 3
• 238000009227 behaviour therapy Methods 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 238000009395 breeding Methods 0.000 description 3
• 230000001488 breeding effect Effects 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 239000003184 complementary RNA Substances 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 235000013861 fat-free Nutrition 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 230000007387 gliosis Effects 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 238000000265 homogenisation Methods 0.000 description 3
• 229910052739 hydrogen Inorganic materials 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• 238000013388 immunohistochemistry analysis Methods 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 239000006166 lysate Substances 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 230000006386 memory function Effects 0.000 description 3
• 210000002418 meninge Anatomy 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 235000013336 milk Nutrition 0.000 description 3
• 239000008267 milk Substances 0.000 description 3
• 210000004080 milk Anatomy 0.000 description 3
• 230000000877 morphologic effect Effects 0.000 description 3
• 230000004660 morphological change Effects 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• 210000004498 neuroglial cell Anatomy 0.000 description 3
• 230000016273 neuron death Effects 0.000 description 3
• 230000007171 neuropathology Effects 0.000 description 3
• 229920001778 nylon Polymers 0.000 description 3
• 238000001543 one-way ANOVA Methods 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 229920001184 polypeptide Polymers 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 238000001742 protein purification Methods 0.000 description 3
• 238000011002 quantification Methods 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 210000000130 stem cell Anatomy 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 239000003656 tris buffered saline Substances 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
• 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
• 238000010173 Alzheimer-disease mouse model Methods 0.000 description 2
• 208000037259 Amyloid Plaque Diseases 0.000 description 2
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
• 108020005544 Antisense RNA Proteins 0.000 description 2
• 101100034357 Arabidopsis thaliana RIPK gene Proteins 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 238000000035 BCA protein assay Methods 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• WKDNQONLGXOZRG-HRNNMHKYSA-N CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 Chemical compound CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 WKDNQONLGXOZRG-HRNNMHKYSA-N 0.000 description 2
• 241000282465 Canis Species 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 208000028698 Cognitive impairment Diseases 0.000 description 2
• 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• 241000282324 Felis Species 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• 108020005004 Guide RNA Proteins 0.000 description 2
• 101000868472 Homo sapiens Sialoadhesin Proteins 0.000 description 2
• 101100264173 Homo sapiens XIAP gene Proteins 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
• 108091054455 MAP kinase family Proteins 0.000 description 2
• 102000043136 MAP kinase family Human genes 0.000 description 2
• 108010031099 Mannose Receptor Proteins 0.000 description 2
• MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
• 102000012064 NLR Proteins Human genes 0.000 description 2
• 108091005686 NOD-like receptors Proteins 0.000 description 2
• 241001123225 Naumovozyma castellii Species 0.000 description 2
• 101710122928 Nucleotide-binding oligomerization domain-containing protein 1 Proteins 0.000 description 2
• 102000016187 PAZ domains Human genes 0.000 description 2
• 108050004670 PAZ domains Proteins 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• 108010013639 Peptidoglycan Proteins 0.000 description 2
• 229940122907 Phosphatase inhibitor Drugs 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 102100022033 Presenilin-1 Human genes 0.000 description 2
• 239000012083 RIPA buffer Substances 0.000 description 2
• 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
• 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
• 230000004570 RNA-binding Effects 0.000 description 2
• 238000003559 RNA-seq method Methods 0.000 description 2
• 238000010459 TALEN Methods 0.000 description 2
• 108091036066 Three prime untranslated region Proteins 0.000 description 2
• 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
• 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 2
• 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
• SPCMQFLNOVTUBM-UHFFFAOYSA-N [7-(dimethylazaniumyl)-10h-phenothiazin-3-yl]-dimethylazanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=C([NH+](C)C)C=C2SC3=CC([NH+](C)C)=CC=C3NC2=C1 SPCMQFLNOVTUBM-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 238000013019 agitation Methods 0.000 description 2
• 150000001413 amino acids Chemical group 0.000 description 2
• 239000003708 ampul Substances 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 230000006736 behavioral deficit Effects 0.000 description 2
• 230000003542 behavioural effect Effects 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000002146 bilateral effect Effects 0.000 description 2
• 230000031018 biological processes and functions Effects 0.000 description 2
• 229960000074 biopharmaceutical Drugs 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 238000010822 cell death assay Methods 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 229960004926 chlorobutanol Drugs 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 208000010877 cognitive disease Diseases 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 230000003413 degradative effect Effects 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000002612 dispersion medium Substances 0.000 description 2
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
• 230000004771 dopaminergic neurodegeneration Effects 0.000 description 2
• 230000003291 dopaminomimetic effect Effects 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 238000001378 electrochemiluminescence detection Methods 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 230000001159 endocytotic effect Effects 0.000 description 2
• 239000003797 essential amino acid Substances 0.000 description 2
• 235000020776 essential amino acid Nutrition 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
• 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 102000056960 human SIGLEC1 Human genes 0.000 description 2
• 150000002431 hydrogen Chemical class 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 238000005462 in vivo assay Methods 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 150000002484 inorganic compounds Chemical class 0.000 description 2
• 229910010272 inorganic material Inorganic materials 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 238000000185 intracerebroventricular administration Methods 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 108020004084 membrane receptors Proteins 0.000 description 2
• GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 239000002679 microRNA Substances 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
• AACUJFVOHGRMTR-DPXNYUHVSA-N n-[3-[(4as,5r,7as)-2-amino-5-methyl-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-(difluoromethyl)pyrazine-2-carboxamide Chemical compound C=1C=C(F)C([C@]23CO[C@@H]([C@H]2CSC(N)=N3)C)=CC=1NC(=O)C1=CN=C(C(F)F)C=N1 AACUJFVOHGRMTR-DPXNYUHVSA-N 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 230000021597 necroptosis Effects 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 230000003188 neurobehavioral effect Effects 0.000 description 2
• 230000000324 neuroprotective effect Effects 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 150000002894 organic compounds Chemical class 0.000 description 2
• 238000004091 panning Methods 0.000 description 2
• 108010089193 pattern recognition receptors Proteins 0.000 description 2
• 102000007863 pattern recognition receptors Human genes 0.000 description 2
• 230000011340 peptidyl-tyrosine autophosphorylation Effects 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 229960003742 phenol Drugs 0.000 description 2
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 150000003077 polyols Chemical class 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 230000004850 protein–protein interaction Effects 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 229940054269 sodium pyruvate Drugs 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 238000002723 toxicity assay Methods 0.000 description 2
• 238000012549 training Methods 0.000 description 2
• 238000001665 trituration Methods 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 210000001364 upper extremity Anatomy 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
• PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
• 108020004463 18S ribosomal RNA Proteins 0.000 description 1
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
• 241000219194 Arabidopsis Species 0.000 description 1
• 108010002913 Asialoglycoproteins Proteins 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 102100040355 Autophagy-related protein 16-1 Human genes 0.000 description 1
• 102100021257 Beta-secretase 1 Human genes 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 101150018129 CSF2 gene Proteins 0.000 description 1
• 101150069031 CSN2 gene Proteins 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 108020004394 Complementary RNA Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000938605 Crocodylia Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 102000009058 Death Domain Receptors Human genes 0.000 description 1
• 108010049207 Death Domain Receptors Proteins 0.000 description 1
• 102000010170 Death domains Human genes 0.000 description 1
• 108050001718 Death domains Proteins 0.000 description 1
• 108091027757 Deoxyribozyme Proteins 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 108091092584 GDNA Proteins 0.000 description 1
• 208000003098 Ganglion Cysts Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 108010077223 Homer Scaffolding Proteins Proteins 0.000 description 1
• 102000010029 Homer Scaffolding Proteins Human genes 0.000 description 1
• 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
• 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
• 101000964092 Homo sapiens Autophagy-related protein 16-1 Proteins 0.000 description 1
• 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
• 101100192145 Homo sapiens PSEN1 gene Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 102100023915 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 229940125966 JNJ-54861911 Drugs 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
• 108010001831 LDL receptors Proteins 0.000 description 1
• 102000000853 LDL receptors Human genes 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 101710128836 Large T antigen Proteins 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
• 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108060004795 Methyltransferase Proteins 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
• 206010061296 Motor dysfunction Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
• MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
• 108091008099 NLRP3 inflammasome Proteins 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 108700019961 Neoplasm Genes Proteins 0.000 description 1
• 102000048850 Neoplasm Genes Human genes 0.000 description 1
• 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• 101710160107 Outer membrane protein A Proteins 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 101710092489 Protein kinase 2 Proteins 0.000 description 1
• 102100031269 Putative peripheral benzodiazepine receptor-related protein Human genes 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 108091005487 SCARB1 Proteins 0.000 description 1
• 241000235343 Saccharomycetales Species 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 241000251131 Sphyrna Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 240000000278 Syzygium polyanthum Species 0.000 description 1
• 241000589499 Thermus thermophilus Species 0.000 description 1
• 108010076830 Thionins Proteins 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108020000411 Toll-like receptor Proteins 0.000 description 1
• 102000002689 Toll-like receptor Human genes 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
• 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 108020000999 Viral RNA Proteins 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 229930003779 Vitamin B12 Natural products 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 229950008995 aducanumab Drugs 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
• 229960003805 amantadine Drugs 0.000 description 1
• 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000007131 anti Alzheimer effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000648 anti-parkinson Effects 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000000939 antiparkinson agent Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• VLLFGVHGKLDDLW-SFHVURJKSA-N atabecestat Chemical compound C=1C(NC(=O)C=2N=CC(=CC=2)C#N)=CC=C(F)C=1[C@]1(C)C=CSC(N)=N1 VLLFGVHGKLDDLW-SFHVURJKSA-N 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000004900 autophagic degradation Effects 0.000 description 1
• 230000004642 autophagic pathway Effects 0.000 description 1
• 230000007455 autophagic response Effects 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
• 229960001081 benzatropine Drugs 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
• 230000007278 cognition impairment Effects 0.000 description 1
• 230000003920 cognitive function Effects 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 101150055601 cops2 gene Proteins 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229950001954 crenezumab Drugs 0.000 description 1
• 238000012866 crystallographic experiment Methods 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 229960003964 deoxycholic acid Drugs 0.000 description 1
• 239000005549 deoxyribonucleoside Substances 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 230000009274 differential gene expression Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 230000003467 diminishing effect Effects 0.000 description 1
• 238000011979 disease modifying therapy Methods 0.000 description 1
• 229960003530 donepezil Drugs 0.000 description 1
• 210000005064 dopaminergic neuron Anatomy 0.000 description 1
• 230000002222 downregulating effect Effects 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229950009694 elenbecestat Drugs 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
• 229960003337 entacapone Drugs 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 238000007667 floating Methods 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 210000005153 frontal cortex Anatomy 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 229960003980 galantamine Drugs 0.000 description 1
• ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
• 229950002508 gantenerumab Drugs 0.000 description 1
• 238000003633 gene expression assay Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 108010064060 high density lipoprotein receptors Proteins 0.000 description 1
• 102000054823 high-density lipoprotein particle receptor activity proteins Human genes 0.000 description 1
• 102000046783 human APP Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 150000002433 hydrophilic molecules Chemical class 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000010189 intracellular transport Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 231100001231 less toxic Toxicity 0.000 description 1
• 229960004502 levodopa Drugs 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
• 229960004640 memantine Drugs 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 238000001000 micrograph Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 230000000051 modifying effect Effects 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• VBMPTAUGUUBFJK-FGJQBABTSA-N n,n-dimethyl-2-[(2r)-6-[(4-phenylphenyl)methoxy]-1,2,3,4-tetrahydronaphthalen-2-yl]ethanamine;hydrate;hydrochloride Chemical compound O.Cl.C([C@H](CC1=CC=2)CCN(C)C)CC1=CC=2OCC(C=C1)=CC=C1C1=CC=CC=C1 VBMPTAUGUUBFJK-FGJQBABTSA-N 0.000 description 1
• IBONACLSSOLHFU-XLSKCSLXSA-N n-[(3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]acetamide Chemical compound CC(=O)NC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O IBONACLSSOLHFU-XLSKCSLXSA-N 0.000 description 1
• YHYKUSGACIYRML-KRWDZBQOSA-N n-[3-[(5r)-3-amino-2,5-dimethyl-1,1-dioxo-6h-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide Chemical compound C1S(=O)(=O)N(C)C(N)=N[C@]1(C)C1=CC(NC(=O)C=2N=CC(F)=CC=2)=CC=C1F YHYKUSGACIYRML-KRWDZBQOSA-N 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000002232 neuromuscular Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 102000044158 nucleic acid binding protein Human genes 0.000 description 1
• 108700020942 nucleic acid binding protein Proteins 0.000 description 1
• 238000006384 oligomerization reaction Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 230000007505 plaque formation Effects 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 229950008885 polyglycolic acid Drugs 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 229960003089 pramipexole Drugs 0.000 description 1
• FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 230000008741 proinflammatory signaling process Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
• 229960000245 rasagiline Drugs 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 238000012827 research and development Methods 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 238000002473 ribonucleic acid immunoprecipitation Methods 0.000 description 1
• 239000002342 ribonucleoside Substances 0.000 description 1
• 229960004136 rivastigmine Drugs 0.000 description 1
• 229920002477 rna polymer Polymers 0.000 description 1
• 229960001879 ropinirole Drugs 0.000 description 1
• UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
• KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
• 229960003179 rotigotine Drugs 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
• 229960003946 selegiline Drugs 0.000 description 1
• 230000037152 sensory function Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 229950007874 solanezumab Drugs 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 230000006886 spatial memory Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000010245 stereological analysis Methods 0.000 description 1
• 239000008227 sterile water for injection Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000003033 structure based virtual screening Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 108091008743 testicular receptors 4 Proteins 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 229960004603 tolcapone Drugs 0.000 description 1
• MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 229960001032 trihexyphenidyl Drugs 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 229950003000 verubecestat Drugs 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000031836 visual learning Effects 0.000 description 1
• 235000019163 vitamin B12 Nutrition 0.000 description 1
• 239000011715 vitamin B12 Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1